Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of JNJ-67835989 in Healthy Participants
NCT04844411Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-67835989 in major depressive disorder (MDD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Abnormalities in Vital Signs up to 6 weeks, Number of Participants with Clinically Significant Clinical Laboratory Abnormalities up to 6 weeks and 6 more. Started Apr 2021; status: completed.
02
Drugs
JNJ-67835989
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04844411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04844411.